NCT00035061已完成2 期
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 20
研究概览
简要总结
Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
- •You must have at least one tumor that can be physically measured or scanned by x-ray.
- •You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.
排除标准
- •You may not have used an experimental medicine or device within the past month.
- •Cancer that has spread to your brain.
- •If you are unwilling or unable to take folic acid or vitamin B12 supplements.
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumUrologic NeoplasmsNCT00034593Eli Lilly and Company
已完成
2 期
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or AbdomenMesotheliomaLung NeoplasmsNon-small Cell Lung CancerNCT00316225Eli Lilly and Company31
已完成
2 期
Pemetrexed as the First Treatment in Advanced or Metastatic Breast CancerBreast Neoplasms, MaleCarcinoma, DuctalBreast CancerNCT00106002Eli Lilly and Company37
终止
2 期
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder CancerUrinary Bladder NeoplasmsNCT02560038The University of Texas Health Science Center, Houston3
已完成
2 期
A Trial for Patients With Advanced/Recurrent Cervical CancerUterine NeoplasmsGenital Neoplasms, FemaleCervical Intraepithelial NeoplasiaNCT00190983Eli Lilly and Company29
